NASDAQ:ENTA - Enanta Pharmaceuticals Stock Price, Forecast & News

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) released its quarterly earnings data on Thursday, November, 21st. The biotechnology company reported $0.44 EPS for the quarter, missing analysts' consensus estimates of $0.56 by $0.12. The biotechnology company earned $51.30 million during the quarter, compared to analyst estimates of $55.95 million. Enanta Pharmaceuticals had a return on equity of 10.46% and a net margin of 22.60%. The business's revenue for the quarter was down 23.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.30 EPS. View Enanta Pharmaceuticals' Earnings History.

Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Enanta Pharmaceuticals.

4 brokerages have issued 1 year price targets for Enanta Pharmaceuticals' stock. Their forecasts range from $57.00 to $130.00. On average, they anticipate Enanta Pharmaceuticals' share price to reach $101.33 in the next twelve months. This suggests a possible upside of 81.4% from the stock's current price. View Analyst Price Targets for Enanta Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Enanta Pharmaceuticals.

Headlines about ENTA stock have been trending somewhat positive on Thursday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Enanta Pharmaceuticals earned a coverage optimism score of 1.6 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Enanta Pharmaceuticals.

Enanta Pharmaceuticals saw a increase in short interest in December. As of December 13th, there was short interest totalling 2,440,000 shares, an increase of 7.0% from the November 28th total of 2,280,000 shares. Based on an average daily trading volume, of 197,600 shares, the days-to-cover ratio is presently 12.3 days. Currently, 14.1% of the company's stock are short sold. View Enanta Pharmaceuticals' Current Options Chain.

Some companies that are related to Enanta Pharmaceuticals include Evotec (EVTCY), Allakos (ALLK), United Therapeutics (UTHR), BridgeBio Pharma (BBIO), Nektar Therapeutics (NKTR), Blueprint Medicines (BPMC), FibroGen (FGEN), SAGE Therapeutics (SAGE), Mirati Therapeutics (MRTX), GW Pharmaceuticals PLC- (GWPH), Ultragenyx Pharmaceutical (RARE), Deciphera Pharmaceuticals (DCPH), PTC Therapeutics (PTCT), HUTCHISON CHINA/S (HCM) and Taro Pharmaceutical Industries (TARO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Verizon Communications (VZ), HCA Healthcare (HCA), Pandora Media (P), Ryder System (R), Tandem Diabetes Care (TNDM), NVIDIA (NVDA), Wells Fargo & Co (WFC), Ford Motor (F), Alibaba Group (BABA) and Tesla (TSLA).

Enanta Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.06%), Wedge Capital Management L L P NC (0.03%), Louisiana State Employees Retirement System (0.03%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own Enanta Pharmaceuticals stock include Bruce L A Carter, George Golumbeski, Jay R Luly, Nathalie Adda, Nathaniel S Gardiner, Paul J Mellett, Tim Ocain and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.

ENTA stock was sold by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System and State of Alaska Department of Revenue. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Bruce L A Carter, George Golumbeski, Nathaniel S Gardiner, Paul J Mellett and Yat Sun Or. View Insider Buying and Selling for Enanta Pharmaceuticals.

ENTA stock was bought by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for Enanta Pharmaceuticals.

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ENTA stock can currently be purchased for approximately $55.85.

Enanta Pharmaceuticals has a market capitalization of $1.11 billion and generates $205.20 million in revenue each year. The biotechnology company earns $46.38 million in net income (profit) each year or $2.21 on an earnings per share basis. Enanta Pharmaceuticals employs 113 workers across the globe.View Additional Information About Enanta Pharmaceuticals.

The official website for Enanta Pharmaceuticals is http://www.enanta.com/.

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]